Dr. Carl June from the University of Pennsylvania has paved the way for innovative cancer treatment, specifically in his discoveries in CAR T-cell therapy. His hard work and dedication in immunotherapy and cancer research over two decades has transformed the treatment process for cancer patients worldwide.

Dr. June's extensive background in cellular immunotherapy led to the development of the chimeric antigen receptor (CAR) T-cell therapy. This drug, Kymirah, became the first FDA-approved cellular therapy in 2017 which has revolutionized the treatment process for blood cancers.

In hopes of advancing cancer treatment, Dr. June is working to target different forms of cancer, like solid tumors. He believes that the potential of CAR T-cell therapy does not stop at treating blood cancers, but can also be a transformative drug in treating autoimmune diseases and solid cancers.

In an interview with Philadelphia Business Journal reporter John George, Dr. June explains how he envisions Philadelphia as the center for cell and gene therapy, which is why he calls it "Cellicon Valley”. Follow the link below to hear more about Dr. June and his plans to shape the future of cancer treatment.

https://www.bizjournals.com/philadelphia/news/2024/01/25/carl-june-penn-cell-therapy-pioneer.html

We are grateful to have such innovative and dedicated doctors at Penn Medicine like Dr. Carl June who continues to work everyday to create a better future for cancer patients.